| Year |
Citation |
Score |
| 2021 |
Bordone MP, Damianich A, Bernardi MA, Eidelman T, Sanz-Blasco S, Gershanik OS, Avale ME, Ferrario JE. Fyn knockdown prevents levodopa-induced dyskinesia in a mouse model of Parkinson's disease. Eneuro. PMID 34099487 DOI: 10.1523/ENEURO.0559-20.2021 |
0.798 |
|
| 2019 |
Bernardi A, Ballestero P, Schenk M, Ferrario M, Gómez G, Rivero R, Avale E, Taravini I, Gershanik O, Guerrero S, Ferrario JE. Yerba mate (Ilex paraguariensis) favors survival and growth of dopaminergic neurons in culture. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30938849 DOI: 10.1002/Mds.27667 |
0.724 |
|
| 2018 |
Lizarraga KJ, Thompson PD, Moore HP, Mizraji G, Gershanik OS, Singer C, Lang AE. Dancing Dorsal Quadrilaterals: A Novel Peripherally Induced Movement Disorder. Jama Neurology. PMID 30556833 DOI: 10.1001/jamaneurol.2018.3948 |
0.717 |
|
| 2018 |
Esteves S, Gleichgerrcht E, Torralva T, Chade A, Gómez Arévalo G, Gershanik O, Manes F, Roca M. Performance of Patients with Early Parkinson Disease on an Executive and Social Cognition Battery. Cognitive and Behavioral Neurology : Official Journal of the Society For Behavioral and Cognitive Neurology. 31: 142-150. PMID 30239464 DOI: 10.1097/Wnn.0000000000000159 |
0.734 |
|
| 2018 |
Skorvanek M, Martinez-Martin P, Kovacs N, Zezula I, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Aviles-Olmos I, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Benchetrit E, ... ... Gershanik O, et al. Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. Parkinsonism & Related Disorders. PMID 29625875 DOI: 10.1016/J.Parkreldis.2018.03.027 |
0.709 |
|
| 2018 |
Stefani A, Heidbreder A, Brandauer E, Guaita M, Neier LM, Mitterling T, Santamaria J, Iranzo A, Videnovic A, Trenkwalder C, Sixel-Döring F, Wenning GK, Chade A, Poewe W, Gershanik OS, et al. Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. Sleep. 41. PMID 29554362 DOI: 10.1093/Sleep/Zsy053 |
0.722 |
|
| 2017 |
Sanchez Abraham M, Gomez Arevalo GJ, Garcia SS, Gershanik OS. A Functional Parkinsonian Tremor in a Pediatric Patient. Movement Disorders Clinical Practice. 4: 275-276. PMID 30838268 DOI: 10.1002/Mdc3.12414 |
0.553 |
|
| 2017 |
Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol JC, Taba P, Seppi K, Levin O, Schrag A, Foltynie T, Alvarez-Sanchez M, Arakaki T, Aschermann Z, Aviles-Olmos I, Benchetrit E, ... ... Gershanik O, et al. Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. Movement Disorders Clinical Practice. 4: 536-544. PMID 30363418 DOI: 10.1002/Mdc3.12476 |
0.757 |
|
| 2017 |
Sanchez Abraham M, Gomez Arevalo G, Garcia SS, Mizraji G, Chade A, Gershanik O. Decreased Palpebral Fissure in Patients with Parkinson's Disease. Movement Disorders Clinical Practice. 4: 58-61. PMID 30363399 DOI: 10.1002/Mdc3.12346 |
0.796 |
|
| 2017 |
Gomez G, Saborido MD, Alejandra Bernardi M, Gershanik OS, Taravini IR, Ferrario JE. Regulation of Pleiotrophin and Fyn in the striatum of rats undergoing L-DOPA-induced dyskinesia. Neuroscience Letters. 666: 5-10. PMID 29241709 DOI: 10.1016/J.Neulet.2017.12.024 |
0.792 |
|
| 2017 |
Sanz-Blasco S, Bordone MP, Damianich A, Gomez G, Bernardi MA, Isaja L, Taravini IR, Hanger DP, Avale ME, Gershanik OS, Ferrario JE. The Kinase Fyn As a Novel Intermediate in L-DOPA-Induced Dyskinesia in Parkinson's Disease. Molecular Neurobiology. PMID 28840468 DOI: 10.1007/S12035-017-0748-3 |
0.792 |
|
| 2015 |
Torralva T, Laffaye T, Báez S, Gleichgerrcht E, Bruno D, Chade A, Ibañez A, Manes F, Gershanik O, Roca M. Verbal Fluency as a Rapid Screening Test for Cognitive Impairment in Early Parkinson's Disease. The Journal of Neuropsychiatry and Clinical Neurosciences. appineuropsych140601. PMID 26067437 DOI: 10.1176/Appi.Neuropsych.14060139 |
0.742 |
|
| 2015 |
Taravini IR, Larramendy C, Gomez G, Saborido MD, Spaans F, Fresno C, González GA, Fernández E, Murer MG, Gershanik OS. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease. Neuropharmacology. PMID 25963416 DOI: 10.1016/J.Neuropharm.2015.04.018 |
0.789 |
|
| 2015 |
Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, et al. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 22: 37-43. PMID 23607783 DOI: 10.1111/Ene.12165 |
0.747 |
|
| 2015 |
Taravini IR, Larramendy C, Gomez G, Saborido MD, Spaans F, Fresno C, González GA, Fernández E, Murer MG, Gershanik OS. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease Neuropharmacology. DOI: 10.1016/j.neuropharm.2015.04.018 |
0.778 |
|
| 2014 |
Kargieman L, Herrera E, Baez S, García AM, Dottori M, Gelormini C, Manes F, Gershanik O, Ibáñez A. Motor-Language Coupling in Huntington's Disease Families. Frontiers in Aging Neuroscience. 6: 122. PMID 24971062 DOI: 10.3389/Fnagi.2014.00122 |
0.326 |
|
| 2014 |
Scocco DH, Wagner JN, Racosta J, Chade A, Gershanik OS. Subjective visual vertical in Pisa syndrome. Parkinsonism & Related Disorders. 20: 878-83. PMID 24857768 DOI: 10.1016/J.Parkreldis.2014.04.030 |
0.764 |
|
| 2014 |
Cardona JF, Kargieman L, Sinay V, Gershanik O, Gelormini C, Amoruso L, Roca M, Pineda D, Trujillo N, Michon M, GarcÃa AM, Szenkman D, Bekinschtein T, Manes F, Ibáñez A. How embodied is action language? Neurological evidence from motor diseases. Cognition. 131: 311-22. PMID 24594627 DOI: 10.1016/J.Cognition.2014.02.001 |
0.68 |
|
| 2014 |
Martínez-Martín P, Rodríguez-Blázquez C, Forjaz MJ, Alvarez-Sánchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martínez-Castrillo JC, Mendoza-Rodríguez A, Moore HP, Rodríguez-Violante M, Singer C, et al. Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 21: 519-24. PMID 24447695 DOI: 10.1111/Ene.12349 |
0.754 |
|
| 2014 |
Högl B, Agostino PV, Peralta MC, Gershanik O, Golombek DA. Alterations in time estimation in multiple system atrophy Basal Ganglia. 4: 95-99. DOI: 10.1016/J.Baga.2014.06.004 |
0.522 |
|
| 2013 |
Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, et al. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism & Related Disorders. 19: 889-93. PMID 23791519 DOI: 10.1016/J.Parkreldis.2013.05.017 |
0.752 |
|
| 2013 |
Cardona JF, Gershanik O, Gelormini-Lezama C, Houck AL, Cardona S, Kargieman L, Trujillo N, Arévalo A, Amoruso L, Manes F, Ibáñez A. Action-verb processing in Parkinson's disease: new pathways for motor-language coupling. Brain Structure & Function. 218: 1355-73. PMID 23412746 DOI: 10.1007/S00429-013-0510-1 |
0.699 |
|
| 2013 |
Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, et al. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Journal of Neurology. 260: 228-36. PMID 22865238 DOI: 10.1007/S00415-012-6624-1 |
0.727 |
|
| 2013 |
Ibáñez A, Cardona JF, Dos Santos YV, Blenkmann A, Aravena P, Roca M, Hurtado E, Nerguizian M, Amoruso L, Gómez-Arévalo G, Chade A, Dubrovsky A, Gershanik O, Kochen S, Glenberg A, et al. Motor-language coupling: direct evidence from early Parkinson's disease and intracranial cortical recordings. Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. 49: 968-84. PMID 22482695 DOI: 10.1016/J.Cortex.2012.02.014 |
0.775 |
|
| 2012 |
Roca M, Manes F, Chade A, Gleichgerrcht E, Gershanik O, Arévalo GG, Torralva T, Duncan J. The relationship between executive functions and fluid intelligence in Parkinson's disease. Psychological Medicine. 42: 2445-52. PMID 22440401 DOI: 10.1017/S0033291712000451 |
0.769 |
|
| 2012 |
Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 19: 1502-8. PMID 22221452 DOI: 10.1111/J.1468-1331.2011.03593.X |
0.416 |
|
| 2011 |
Taravini IR, Chertoff M, Cafferata EG, Courty J, Murer MG, Pitossi FJ, Gershanik OS. Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats. Molecular Neurodegeneration. 6: 40. PMID 21649894 DOI: 10.1186/1750-1326-6-40 |
0.776 |
|
| 2010 |
Roca M, Torralva T, Gleichgerrcht E, Chade A, Arévalo GG, Gershanik O, Manes F. Impairments in social cognition in early medicated and unmedicated Parkinson disease. Cognitive and Behavioral Neurology : Official Journal of the Society For Behavioral and Cognitive Neurology. 23: 152-8. PMID 20829664 DOI: 10.1097/Wnn.0B013E3181E078De |
0.746 |
|
| 2008 |
Chade A, Roca M, Torralva T, Gleichgerrcht E, Fabbro N, Arévalo GG, Gershanik O, Manes F. Detecting cognitive impairment in patients with Parkinson's disease with a brief cognitive screening tool: the Addenbrooke's Cognitive Examination (ACE). Dementia & Neuropsychologia. 2: 197-200. PMID 29213570 DOI: 10.1590/S1980-57642009Dn20300006 |
0.758 |
|
| 2008 |
Larramendy C, Taravini IR, Saborido MD, Ferrario JE, Murer MG, Gershanik OS. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. Behavioural Brain Research. 194: 44-51. PMID 18638507 DOI: 10.1016/J.Bbr.2008.06.021 |
0.78 |
|
| 2007 |
Delfino M, Kalisch R, Czisch M, Larramendy C, Ricatti J, Taravini IR, Trenkwalder C, Murer MG, Auer DP, Gershanik OS. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1911-21. PMID 17287822 DOI: 10.1038/Sj.Npp.1301329 |
0.795 |
|
| 2005 |
Taravini IR, Ferrario JE, Delbe J, Ginestet L, Debeir T, Courty J, Murer MG, Gershanik OS, Raisman-Vozari R. Immunodetection of heparin-binding growth associated molecule (pleiotrophin) in striatal interneurons. Brain Research. 1066: 196-200. PMID 16325783 DOI: 10.1016/J.Brainres.2005.10.055 |
0.791 |
|
| 2005 |
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, Yebenes JD, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, et al. Erratum: Levodopa in the treatment of Parkinson's disease: Current controversies (Movement Disorders) (2004)) Movement Disorders. 20. DOI: 10.1002/Mds.20519 |
0.368 |
|
| 2004 |
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Bonucelli U, Damier P, De Yebenes J, Gershanik O, Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Movement Disorders : Official Journal of the Movement Disorder Society. 19: 997-1005. PMID 15372588 DOI: 10.1002/Mds.20243 |
0.455 |
|
| 2004 |
Ferrario JE, Taravini IR, Mourlevat S, Stefano A, Delfino MA, Raisman-Vozari R, Murer MG, Ruberg M, Gershanik O. Differential gene expression induced by chronic levodopa treatment in the striatum of rats with lesions of the nigrostriatal system. Journal of Neurochemistry. 90: 1348-58. PMID 15341519 DOI: 10.1111/J.1471-4159.2004.02595.X |
0.799 |
|
| 2004 |
Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Cns Drugs. 18: 733-46. PMID 15330687 DOI: 10.2165/00023210-200418110-00003 |
0.444 |
|
| 2004 |
Delfino MA, Stefano AV, Ferrario JE, Taravini IR, Murer MG, Gershanik OS. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. Behavioural Brain Research. 152: 297-306. PMID 15196797 DOI: 10.1016/J.Bbr.2003.10.009 |
0.817 |
|
| 2003 |
Ferrario JE, Delfino MA, Stefano AV, Zbarsky V, Douhou A, Murer MG, Raisman-Vozari R, Gershanik OS. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neuroscience Research. 47: 431-6. PMID 14630347 DOI: 10.1016/j.neures.2003.08.001 |
0.803 |
|
| 2001 |
Högl B, Peralta C, Wetter TC, Gershanik O, Trenkwalder C. Effect of sleep deprivation on motor performance in patients with Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 616-21. PMID 11481684 DOI: 10.1002/Mds.1138 |
0.745 |
|
| 2001 |
Ferrario J, Murer MG, Raisman-Vozari R, Gershanik O. Chronic levodopa for Parkinson's disease: Beyond toxicity Focus On Parkinson's Disease. 13: 32-36. |
0.654 |
|
| 2000 |
Tseng KY, Roubert C, Do L, Rubinstein M, Kelly MA, Grandy DK, Low MJ, Gershanik OS, Murer MG, Giros B, Raisman-Vozari R. Selective increase of Nurr1 mRNA expression in mesencephalic dopaminergic neurons of D2 dopamine receptor-deficient mice. Brain Research. Molecular Brain Research. 80: 1-6. PMID 11039723 DOI: 10.1016/S0169-328X(00)00107-8 |
0.643 |
|
| 2000 |
Murer MG, Dziewczapolski G, Salin P, Vila M, Tseng KY, Ruberg M, Rubinstein M, Kelly MA, Grandy DK, Low MJ, Hirsch E, Raisman-Vozari R, Gershanik O. The indirect basal ganglia pathway in dopamine D(2) receptor-deficient mice. Neuroscience. 99: 643-50. PMID 10974427 DOI: 10.1016/S0306-4522(00)00223-2 |
0.8 |
|
| 2000 |
Lera G, Scipioni O, Garcia S, Cammarota A, Fischbein G, Gershanik O. A combined pattern of movement disorders resulting from posterolateral thalamic lesions of a vascular nature: a syndrome with clinico-radiologic correlation. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 120-6. PMID 10634250 DOI: 10.1002/1531-8257(200001)15:1<120::Aid-Mds1018>3.0.Co;2-V |
0.757 |
|
| 1999 |
Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 911-3. PMID 10584663 DOI: 10.1002/1531-8257(199911)14:6<911::Aid-Mds1001>3.0.Co;2-H |
0.409 |
|
| 1999 |
Menalled LB, Dziewczapolski G, Garcia MC, Rubinstein M, Gershanik OS. D3 receptor knockdown through antisense oligonucleotide administration supports its inhibitory role in locomotion. Neuroreport. 10: 3131-6. PMID 10574548 DOI: 10.1097/00001756-199910190-00002 |
0.788 |
|
| 1999 |
Murer MG, Raisman-Vozari R, Gershanik O. Levodopa in Parkinson's disease: neurotoxicity issue laid to rest? Drug Safety. 21: 339-52. PMID 10554050 DOI: 10.2165/00002018-199921050-00001 |
0.474 |
|
| 1999 |
Golbe LI, Di Iorio G, Lazzarini A, Vieregge P, Gershanik OS, Bonavita V, Duvoisin RC. The Contursi kindred, a large family with autosomal dominant Parkinson's disease: implications of clinical and molecular studies. Advances in Neurology. 80: 165-70. PMID 10410717 |
0.534 |
|
| 1999 |
Murer MG, Ferrario J, Delfino M, Dziewczapolski G, Gershanik OS, Raisman-Vozari R. Increased [125I]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions. Neuroreport. 10: 1501-5. PMID 10380970 |
0.69 |
|
| 1998 |
Högl BE, Gómez-Arévalo G, GarcÃa S, Scipioni O, Rubio M, Blanco M, Gershanik OS. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology. 50: 1332-9. PMID 9595983 DOI: 10.1212/Wnl.50.5.1332 |
0.773 |
|
| 1998 |
Dziewczapolski G, Menalled LB, GarcÃa MC, Mora MA, Gershanik OS, Rubinstein M. Opposite roles of D1 and D5 dopamine receptors in locomotion revealed by selective antisense oligonucleotides. Neuroreport. 9: 1-5. PMID 9592037 DOI: 10.1097/00001756-199801050-00001 |
0.782 |
|
| 1998 |
Murer MG, Dziewczapolski G, Menalled LB, GarcÃa MC, Agid Y, Gershanik O, Raisman-Vozari R. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Annals of Neurology. 43: 561-75. PMID 9585350 DOI: 10.1002/Ana.410430504 |
0.796 |
|
| 1998 |
Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs. 55: 23-30. PMID 9483167 DOI: 10.2165/00003495-199855001-00004 |
0.515 |
|
| 1997 |
Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G, Fang Y, Larson JL, McDougall JA, Chester JA, Saez C, Pugsley TA, Gershanik O, Low MJ, Grandy DK. Mice lacking dopamine D4 receptors are supersensitive to ethanol, cocaine, and methamphetamine. Cell. 90: 991-1001. PMID 9323127 DOI: 10.1016/S0092-8674(00)80365-7 |
0.783 |
|
| 1997 |
Salin P, Dziewczapolski G, Gershanik OS, Nieoullon A, Raisman-Vozari R. Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat. Brain Research. Molecular Brain Research. 47: 311-21. PMID 9221930 DOI: 10.1016/S0169-328X(97)00068-5 |
0.75 |
|
| 1997 |
Gomez Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O. Clinical and pharmacological differences in early- versus late-onset Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 12: 277-84. PMID 9159719 DOI: 10.1002/Mds.870120303 |
0.795 |
|
| 1997 |
Dziewczapolski G, Murer G, Agid Y, Gershanik O, Raisman-Vozari R. Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine-lesioned rats. Neuroreport. 8: 975-9. PMID 9141075 DOI: 10.1097/00001756-199703030-00031 |
0.759 |
|
| 1997 |
Dziewczapolski G, Menalled LB, Savino MT, Mora M, Stefano FJ, Gershanik O. Mechanism of action of clozapine-induced modification of motor behavior in an animal model of the "super-off" phenomenon. Movement Disorders : Official Journal of the Movement Disorder Society. 12: 159-66. PMID 9087973 DOI: 10.1002/Mds.870120205 |
0.767 |
|
| 1997 |
Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology. 48: 363-8. PMID 9040722 DOI: 10.1212/Wnl.48.2.363 |
0.499 |
|
| 1997 |
Dziewczapolski G, Mora MA, Menalled LB, Stéfano FJ, Rubinstein M, Gershanik OS. Threshold of dopamine content and D1 receptor stimulation necessary for the expression of rotational behavior induced by D2 receptor stimulation under normo and supersensitive conditions. Naunyn-Schmiedeberg's Archives of Pharmacology. 355: 30-5. PMID 9007839 DOI: 10.1007/Pl00004914 |
0.785 |
|
| 1997 |
Fischbein G, Cammarota A, Scipioni O, Garcia S, Lera G, Gomez Arevalo G, Gershanik O. 5-30-06 Variable clinical presentation of Central Nervous System Whipple's Disease Journal of the Neurological Sciences. 150: S316. DOI: 10.1016/S0022-510X(97)86444-1 |
0.775 |
|
| 1997 |
Rinne U, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso J, Montastruc J, Mardden C. 2-30-28 Cabergoline delays the onset of motor complications in early Parkinson's disease Journal of the Neurological Sciences. 150: S114. DOI: 10.1016/S0022-510X(97)85405-6 |
0.373 |
|
| 1995 |
Cammarota A, Gershanik OS, GarcÃa S, Lera G. Cervical dystonia due to spinal cord ependymoma: involvement of cervical cord segments in the pathogenesis of dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 10: 500-3. PMID 7565833 DOI: 10.1002/Mds.870100416 |
0.654 |
|
| 1992 |
Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Movement Disorders : Official Journal of the Movement Disorder Society. 7: 117-24. PMID 1350058 DOI: 10.1002/Mds.870070204 |
0.822 |
|
| 1990 |
Rubinstein M, Muschietti JP, Gershanik O, Flawia MM, Stefano FJ. Adaptive mechanisms of striatal D1 and D2 dopamine receptors in response to a prolonged reserpine treatment in mice. The Journal of Pharmacology and Experimental Therapeutics. 252: 810-6. PMID 2138223 |
0.46 |
|
| 1989 |
Rubinstein M, Schinder AF, Gershanik O, Stefano FJ. Positive interaction between alpha-1 adrenergic and dopamine-2 receptors in locomotor activity of normo and supersensitive mice. Life Sciences. 44: 337-46. PMID 2536881 DOI: 10.1016/0024-3205(89)90227-0 |
0.503 |
|
| 1989 |
Gershanik OS, Rubinstein M, Stefano F. Inhibitory action of L-dopa. Neurology. 39: 1137. PMID 2527340 DOI: 10.1212/Wnl.39.8.1137-A |
0.381 |
|
| 1988 |
Rubinstein M, Gershanik O, Stefano FJ. Postsynaptic bimodal effect of sulpiride on locomotor activity induced by pergolide in catecholamine-depleted mice. Naunyn-Schmiedeberg's Archives of Pharmacology. 337: 115-7. PMID 3368011 DOI: 10.1007/Bf00169487 |
0.319 |
|
| 1988 |
Gershanik OS, Luquin MR, Scipioni O, Obeso JA. Isoniazid therapy in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 133-9. PMID 3221901 DOI: 10.1002/mds.870030205 |
0.814 |
|
| 1988 |
Gershanik OS, Scipioni O, GarcÃa S. Lisuride infusion pump in Parkinson's disease. A report of two cases. Journal of Neural Transmission. Supplementum. 27: 85-90. PMID 2969955 |
0.79 |
|
| 1988 |
Rubinstein M, Gershanik O, Stefano FJ. Different roles of D-1 and D-2 dopamine receptors involved in locomotor activity of supersensitive mice. European Journal of Pharmacology. 148: 419-26. PMID 2968273 DOI: 10.1016/0014-2999(88)90121-5 |
0.363 |
|
| 1983 |
Gershanik O, Heikkila RE, Duvoisin RC. Effects of dopamine depletion on rotational behavior to dopamine agonists. Brain Research. 261: 358-60. PMID 6831221 DOI: 10.1016/0006-8993(83)90645-5 |
0.559 |
|
| 1983 |
Gershanik O, Heikkila RE, Duvoisin RC. Behavioral correlations of dopamine receptor activation. Neurology. 33: 1489-92. PMID 6605497 DOI: 10.1212/Wnl.33.11.1489 |
0.612 |
|
| 1982 |
Gershanik OS, Heikkila RE, Duvoisin RC, Manzino L. Behavioral correlates of dopamine receptor interaction Neurology. 32: A 161. |
0.51 |
|
| 1979 |
Gershanik OS, Heikkila RE, Duvoisin RC. Asymmetric action of intraventricular monoamine neurotoxins. Brain Research. 174: 345-50. PMID 487133 DOI: 10.1016/0006-8993(79)90860-6 |
0.458 |
|
| 1979 |
Gershanik OS, Heikkila RE, Duvoisin RC. The role of serotonin neurons in the action of L-dopa in an animal model of parkinsonism Neurology. 29: 553. |
0.54 |
|
| 1976 |
Thomson AF, Gershanik OS, Lahitou E. Long term treatment of parkinsonism with L-dopa and alpha methyldopa hydrazine. Our experience | NUESTRA EXPERIENCA EN EL TRATAMIENTO PROLONGADO DE LOS PARKINSONISMOS CON LA ASOCIACION L-DOPA-ALFAMETILDOPA HIDRAZINA Revista Neurologica Argentina. 2: 343-349. |
0.761 |
|
| 1976 |
Thomson AF, Gershanik OS, Lahitou RE. Longterm treatment of parkinsonism with levodopa plus carbidopa | NUESTRA EXPERIENCIA EN EL TRATAMIENTO PROLONGADO DE LOS PARKINSONISMOS CON LA ASOCIACION L DOPO ALFAMETILDOPA HIDRAZINA Revista Neurologica Argentina. 2: 290. |
0.776 |
|
| Show low-probability matches. |